Gallbladder Cancer News and Research

RSS

Gallbladder cancer is a disease in which malignant (cancer) cells form in the tissues of the gallbladder. Gallbladder cancer is a rare disease in which malignant (cancer) cells are found in the tissues of the gallbladder. The gallbladder is a pear-shaped organ that lies just under the liver in the upper abdomen. The gallbladder stores bile, a fluid made by the liver to digest fat. When food is being broken down in the stomach and intestines, bile is released from the gallbladder through a tube called the common bile duct, which connects the gallbladder and liver to the first part of the small intestine.

Researchers identify gene variants that may predispose individuals to develop gallbladder cancer

By comparing the genetic code of gallbladder cancer patients with those of healthy volunteers at nearly 700,000 different locations in the genome, researchers say they have found several gene variants which may predispose individuals to develop the disease.

6 Mar 2017

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer.

1 Sep 2015

Nanoplatform technology that detects early stages of cancer receives U.S. patent

A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear.

17 Jun 2015

Aflatoxin exposure associated with increased risk of gallbladder cancer

In a small study in Chile that included patients with gallbladder cancer, exposure to aflatoxin (a toxin produced by mold) was associated with an increased risk of gallbladder cancer, according to a study in the May 26 issue of JAMA.

27 May 2015

Signostics gets FDA 510k clearance for handheld bladder scanner

Medical device company, Signostics, announced today it has clearance from the U.S. Food and Drug Administration to launch the SignosRT Bladder, the company’s new hand-held bladder scanner.

15 Jan 2015

Overweight and obesity linked to 10 common cancers and over 12 000 cases every year in the UK

A higher body mass index (BMI) increases the risk of developing 10 of the most common cancers, the largest study of its kind on BMI and cancer, involving more than 5 million adults in the UK, published in The Lancet shows.

14 Aug 2014

Viewpoints: Website is like 'a patient bleeding from self-inflicted wounds;' remembering patients who never had care and the need for health law

Obamacare is starting to resemble a patient bleeding from self-inflicted wounds. A month after launch, the online health exchanges where individuals are supposed to shop for insurance remain slow or unusable, except in states that opted to run their own marketplaces and did a more competent job than the administration. As if that weren't trouble enough, critics are justifiably mocking President Obama for his repeated, untrue promise that if people liked their health plans, they could keep them. Oops. Hundreds of thousands of people are getting termination notices for plans that don't meet the strict new requirements of the Affordable Care Act. Presumably, not all those people disliked their plans (11/3).

5 Nov 2013

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE Mark approval to market its Advanix™ Biliary Plastic Stents for the treatment of biliary strictures, including biliary stone disease, benign biliary strictures, and suspected and confirmed malignancies in the biliary system. The product is now available in Europe and other international markets; the Company plans to launch it in the U.S. this quarter.

21 Oct 2010

Cancer patients may live longer with palliative and hospice care services: Study

A new study released by the New England Journal of Medicine found that among patients with non-small-cell lung cancer, those who received palliative care lived, on average, almost two months longer than those who received standard care. Researchers also found that the patients receiving palliative care reported a higher quality of life through the final course of their illness.

20 Aug 2010

High exposure to estrogens may cause gall bladder cancer: Research

A very aggressive disease with a poor prognosis, gallbladder cancer may be connected to higher exposure to estrogens, according to a group of researchers at the University of Houston (UH). Dr. Jan--ke Gustafsson, Robert A. Welch Professor in UH's biology and biochemistry department, described his team's findings in a paper titled "Estrogen-dependent gallbladder carcinogenesis in LXRβ-/- female mice" appearing in a recent issue of the journal Proceedings of the National Academy of Sciences, one of the world's most-cited multidisciplinary scientific serials.

17 Aug 2010

1st Annual Biliary Tract-Gallbladder Cancer Research Symposium to be held at ASCO in Alexandria

CanLiv: The Hepatobiliary Cancers Foundation in partnership with The Cholangiocarcinoma Foundation will host the 1st Annual Biliary Tract-Gallbladder Cancer Research Symposium on Friday, May 7, 2010 at the American Society of Clinical Oncologists (ASCO) headquarters in Alexandria, Virginia.

4 Feb 2010

Research study on EGFR and HER2 expressions in BTC

The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others.

19 Oct 2009

FDA provides 510(k) clearance for Boston Scientific's WallFlex Biliary RX covered stents

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its WallFlex(®) Biliary RX fully and partially covered stents for the palliative treatment of malignant bile duct strictures. The WallFlex Biliary RX uncovered stent was cleared by the FDA in 2006.

6 Oct 2009

Gallbladder Cancer News and Research

Further Reading

Researchers identify gene variants that may predispose individuals to develop gallbladder cancer

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Nanoplatform technology that detects early stages of cancer receives U.S. patent

Aflatoxin exposure associated with increased risk of gallbladder cancer

Signostics gets FDA 510k clearance for handheld bladder scanner

Overweight and obesity linked to 10 common cancers and over 12 000 cases every year in the UK

Viewpoints: Website is like 'a patient bleeding from self-inflicted wounds;' remembering patients who never had care and the need for health law

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Cancer patients may live longer with palliative and hospice care services: Study

High exposure to estrogens may cause gall bladder cancer: Research

1st Annual Biliary Tract-Gallbladder Cancer Research Symposium to be held at ASCO in Alexandria

Research study on EGFR and HER2 expressions in BTC

FDA provides 510(k) clearance for Boston Scientific's WallFlex Biliary RX covered stents

Trial results show better survival for gallbladder and bile duct cancer

Trends in gallbladder cancer over forty years

Overweight children may inherit faster eating behaviour

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News